The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of LY3200882 in Participants With Solid Tumors
Official Title: A Phase 1 Study of LY3200882 in Patients With Solid Tumors
Study ID: NCT02937272
Brief Summary: The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Louisville, Louisville, Kentucky, United States
Weill Cornell Medical College, New York, New York, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Calvary Mater Newcastle, Newcastle, New South Wales, Australia
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
Greenslopes Private Hospital, Greenslopes, Queensland, Australia
Princess Margaret Hospital (Ontario), Lai Chi Kok, Kowloon, Canada
Hopital Saint-Louis, Paris, Cedex 10, France
CHRU de Lille, Lille, , France
Gustave Roussy, Villejuif Cedex, , France
Universitätsklinikum Würzburg A. ö. R., Würzburg, Bayern, Germany
Charité Campus Virchow-Klinikum, Berlin, , Germany
Istituto Clinico Humanitas, Rozzano, Milano, Italy
Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona, , Italy
National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Clínico Universitario de Valencia, Valencia, , Spain
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR